Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1299"
Predicate | Value (sorted: default) |
rdfs:label |
|
rdf:type |
|
?:Evidence_assump_list_id |
"227"
|
?:Evidence_enzyme_system |
|
?:Evidence_type |
|
?:claim_assumed_valid_for_evidence_application_evidence_1548 |
|
?:content |
"route of administration: oral
study duration: Each subject received 50 mg of cinacalcet (25-mg [as free base] film tablets,
Kirin Brewery Co, Ltd, Tokyo, Japan) or a matched
placebo orally once daily for 8 days. On day 8, each
subject also received a single oral dose of 30 mg DEX
(Medicon, 15-mg film tablets, Shionogi & Co, Ltd,
Osaka, Japan).
population: 23 male volunteers
tested for known CYP450 polymorphisms? all participants included in the PK analaysis wer classified as a CYP2D6 extensive metabolizers based on the dextromethorphan/dextorpham metabolic ratio
ages: 20 - 33
description:
The Cmax, AUC(0-t), and AUC(0-inf) of DEX were significantly higher during the cinacalcet treatment than with placebo, with a ratio of 7.481, 14.373, and 11.475, respectively. The Cmax of DOR was decreased, and the AUC(0-t) and AUC(0-inf) of DOR were slightly increased during cinacalcet treatment."
|
dc:creator |
|
dc:date |
"09/25/2009 10:47:42"
|
rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ cinacalcet_inhibits_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1548 }
Context graph